Author:
Kinkhabwala Ali,Herbel Christoph,Pankratz Jennifer,Yushchenko Dmytro A.,Rüberg Silvia,Praveen Paurush,Reiß Sandy,Rodriguez Federico Carlos,Schäfer Daniel,Kollet Jutta,Dittmer Vera,Martinez-Osuna Manuel,Minnerup Lara,Reinhard Claudia,Dzionek Andrzej,Rockel Thomas Dino,Borbe Stefan,Büscher Martin,Krieg Jürgen,Nederlof Michel,Jungblut Melanie,Eckardt Dominik,Hardt Olaf,Dose Christian,Schumann Eik,Peters Ralf-Peter,Miltenyi Stefan,Schmitz Jürgen,Müller Werner,Bosio Andreas
Abstract
AbstractMany critical advances in research utilize techniques that combine high-resolution with high-content characterization at the single cell level. We introduce the MICS (MACSima Imaging Cyclic Staining) technology, which enables the immunofluorescent imaging of hundreds of protein targets across a single specimen at subcellular resolution. MICS is based on cycles of staining, imaging, and erasure, using photobleaching of fluorescent labels of recombinant antibodies (REAfinity Antibodies), or release of antibodies (REAlease Antibodies) or their labels (REAdye_lease Antibodies). Multimarker analysis can identify potential targets for immune therapy against solid tumors. With MICS we analysed human glioblastoma, ovarian and pancreatic carcinoma, and 16 healthy tissues, identifying the pair EPCAM/THY1 as a potential target for chimeric antigen receptor (CAR) T cell therapy for ovarian carcinoma. Using an Adapter CAR T cell approach, we show selective killing of cells only if both markers are expressed. MICS represents a new high-content microscopy methodology widely applicable for personalized medicine.
Publisher
Springer Science and Business Media LLC
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献